Large-scale testing (Phase 3)Study completedNCT00002835What this trial is testingCombination Chemotherapy in Treating Patients With LymphomaWho this might be right forLymphoma M.D. Anderson Cancer Center 116
Early research (Phase 1)Ended earlyNCT02106091What this trial is testingSafety Study to Assess AFM11 in Patients With Relapsed and/or Refractory CD19 Positive B-cell NHLWho this might be right forRelapsed B-Cell Non-Hodgkin LymphomaRefractory B-Cell Non-Hodgkin Lymphoma Affimed GmbH 16
Early research (Phase 1)Ended earlyNCT02978235What this trial is testingA Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or LymphomaWho this might be right forMultiple MyelomaNonHodgkin Lymphoma Taiho Oncology, Inc. 11
Testing effectiveness (Phase 2)Study completedNCT00002697What this trial is testingCombination Chemotherapy Plus Radiation Therapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's LymphomaWho this might be right forLymphoma Memorial Sloan Kettering Cancer Center
Very early researchUnknownNCT04191941What this trial is testingTreatment of Hematological Malignancy With Novel CAR-T Cells.Who this might be right forB-cell Non Hodgkin LymphomaB-cell Acute Lymphoblastic LeukemiaMultiple Myeloma Timmune Biotech Inc. 9
Early research (Phase 1)Looking for participantsNCT06022029What this trial is testingA Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.Who this might be right forTriple Negative Breast CancerDiffuse Large B Cell LymphomaFollicular Lymphoma+11 more OncoNano Medicine, Inc. 168
Testing effectiveness (Phase 2)Ended earlyNCT02384954What this trial is testingQUILT-3.002: N-803 in Patients With Relapse/Refractory iNHL in Conjunction With RituximabWho this might be right forRelapsed/Refractory Indolent B Cell Non-Hodgkin Lymphoma Altor BioScience 43
Testing effectiveness (Phase 2)Study completedNCT00474929What this trial is testingSorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple MyelomaWho this might be right forLymphomaMultiple Myeloma and Plasma Cell Neoplasm Mayo Clinic 103
Testing effectiveness (Phase 2)Active Not RecruitingNCT05507541What this trial is testingTTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell LymphomaWho this might be right forRecurrent ALK Positive Large B-Cell LymphomaRecurrent B-Cell Non-Hodgkin LymphomaRecurrent Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation+25 more Mayo Clinic 10
Large-scale testing (Phase 3)Study completedNCT01321541What this trial is testingComparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell TransplantWho this might be right forDiffuse Large B-cell Lymphomade Novo DLBCLDLBCL Transformed From Indolent Lymphoma+1 more CTI BioPharma 312
Early research (Phase 1)Study completedNCT02290951What this trial is testingStudy to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell MalignanciesWho this might be right forNon-Hodgkin LymphomaChronic Lymphocytic Leukemia Regeneron Pharmaceuticals 200
Large-scale testing (Phase 3)Ended earlyNCT01289223What this trial is testingA Trial to Investigate the Efficacy of Bendamustine in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Refractory to Rituximab.Who this might be right forIndolent B-cell NHL Mundipharma Research Limited 88
Testing effectiveness (Phase 2)Study completedNCT00992446What this trial is testingBortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin LymphomaWho this might be right forAdult Diffuse Large B-Cell LymphomaB-Cell Non-Hodgkin LymphomaFollicular Lymphoma+3 more Fred Hutchinson Cancer Center 27
Early research (Phase 1)UnknownNCT03720496What this trial is testingTreatment of Refractory/Relapsed Non-Hodgkin Lymphoma With CD19-TriCART Cell TherapyWho this might be right forNon-hodgkin Lymphoma,B Cell Timmune Biotech Inc. 6
Testing effectiveness (Phase 2)Study completedNCT00064311What this trial is testingRavuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell TransplantationWho this might be right forBreast CancerChronic Myeloproliferative DisordersGestational Trophoblastic Tumor+9 more National Institutes of Health Clinical Center (CC)
Early research (Phase 1)Study completedNCT00608361What this trial is testingDasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By SurgeryWho this might be right forAdult Acute Lymphoblastic Leukemia in RemissionAdult B Acute Lymphoblastic LeukemiaAdult Hepatocellular Carcinoma+82 more National Cancer Institute (NCI) 80
Testing effectiveness (Phase 2)Study completedNCT00596804What this trial is testingSafety Study of Different Doses of hA20 (Veltuzumab) in CD20+ Non-Hodgkin's LymphomaWho this might be right forNon-Hodgkin's LymphomaLymphoma, DiffuseLymphoma, Diffuse, Mixed Lymphocytic-Histiocytic Gilead Sciences 39
Early research (Phase 1)Study completedNCT00005021What this trial is testingCombination Chemotherapy With or Without Biological Therapy in Treating Patients With Refractory Solid Tumor or LymphomaWho this might be right forLymphomaSmall Intestine CancerUnspecified Adult Solid Tumor, Protocol Specific Fox Chase Cancer Center 17
Testing effectiveness (Phase 2)UnknownNCT00003163What this trial is testingPeripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell CancersWho this might be right forLymphomaMultiple Myeloma and Plasma Cell Neoplasm Medical College of Wisconsin 10
Testing effectiveness (Phase 2)Study completedNCT03397706What this trial is testingDose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV+ Lymphoid MalignanciesWho this might be right forEpstein-Barr Virus-Associated LymphomaLymphoproliferative Disorders Viracta Therapeutics, Inc. 64